The Experts below are selected from a list of 309 Experts worldwide ranked by ideXlab platform
Paolo Macchiarini - One of the best experts on this subject based on the ideXlab platform.
-
technique and results of hyperthermic 41 c isolated lung perfusion with high doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis
European Journal of Cardio-Thoracic Surgery, 2002Co-Authors: C Schröder, Stefan Fisher, Anne Christin Pieck, Hartmut Kirchner, Ulrich Jaehde, Axel Haverich, Axel Muller, Paolo MacchiariniAbstract:Objective: A technique of hyperthermic isolated lung perfusion (ILP) chemotherapy was developed. Methods: Since April 1999, four patients with unilateral (n ¼ 2) or bilateral (n ¼ 2) sarcoma metastasis confined to a lobe (n ¼ 2) or entire lung (n ¼ 2) entered into a pilot study of hyperthermic (418C) ILP with high doses of cisplatin (70 mg/m 2 ). Eligibility included drug resistant metastasis and at least four previous surgical metastasectomies. The ILP of the lung segments was carried out following metastectomy, for 20–40 min at a rate of 0.3–0.5 l/min, a mean perfusion pressure lower than the own mean pulmonary artery pressure, and an Inflow Temperature of 418C or higher. Before and following ILP, the isolated lung segments were flushed with normothermic saline (1 l). Flow was continuously maintained by a centrifugal pump. Results: All patients successfully completed 31.7 ^ 9 min perfusion time at 41.4 ^ 0.38C, and this time-point corresponded to the maximal platinum lung-uptake (93.8 ng/mg tissue). The total vascular isolation was confirmed by continuously low systemic cisplatin plasma levels. There was no systemic drug-related toxicity but all patients experienced transient pulmonary toxicity as noncardiogenic edema of the treated lung segments. With a median follow-up of 12 months, three patients are alive and disease-free and one died from cerebral metastasis without autopsy evidence of local recurrence 13 months following ILP. Conclusion: Hyperthermic perfusion chemotherapy can be done safely and effectively. It represents a new treatment modality and deserves further investigations for patients with advanced, drug resistant or surgically refractory, lung sarcoma metastasis. However, further studies are needed to limit the ILP-induced pulmonary toxicity. q 2002 Elsevier Science B.V. All rights reserved.
-
Technique and results of hyperthermic (41°C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis
European Journal of Cardio-Thoracic Surgery, 2002Co-Authors: C Schröder, Stefan Fisher, Anne Christin Pieck, Hartmut Kirchner, Ulrich Jaehde, Axel Haverich, Axel Muller, Paolo MacchiariniAbstract:Objective: A technique of hyperthermic isolated lung perfusion (ILP) chemotherapy was developed. Methods: Since April 1999, four patients with unilateral (n ¼ 2) or bilateral (n ¼ 2) sarcoma metastasis confined to a lobe (n ¼ 2) or entire lung (n ¼ 2) entered into a pilot study of hyperthermic (418C) ILP with high doses of cisplatin (70 mg/m 2 ). Eligibility included drug resistant metastasis and at least four previous surgical metastasectomies. The ILP of the lung segments was carried out following metastectomy, for 20–40 min at a rate of 0.3–0.5 l/min, a mean perfusion pressure lower than the own mean pulmonary artery pressure, and an Inflow Temperature of 418C or higher. Before and following ILP, the isolated lung segments were flushed with normothermic saline (1 l). Flow was continuously maintained by a centrifugal pump. Results: All patients successfully completed 31.7 ^ 9 min perfusion time at 41.4 ^ 0.38C, and this time-point corresponded to the maximal platinum lung-uptake (93.8 ng/mg tissue). The total vascular isolation was confirmed by continuously low systemic cisplatin plasma levels. There was no systemic drug-related toxicity but all patients experienced transient pulmonary toxicity as noncardiogenic edema of the treated lung segments. With a median follow-up of 12 months, three patients are alive and disease-free and one died from cerebral metastasis without autopsy evidence of local recurrence 13 months following ILP. Conclusion: Hyperthermic perfusion chemotherapy can be done safely and effectively. It represents a new treatment modality and deserves further investigations for patients with advanced, drug resistant or surgically refractory, lung sarcoma metastasis. However, further studies are needed to limit the ILP-induced pulmonary toxicity. q 2002 Elsevier Science B.V. All rights reserved.
C Schröder - One of the best experts on this subject based on the ideXlab platform.
-
technique and results of hyperthermic 41 c isolated lung perfusion with high doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis
European Journal of Cardio-Thoracic Surgery, 2002Co-Authors: C Schröder, Stefan Fisher, Anne Christin Pieck, Hartmut Kirchner, Ulrich Jaehde, Axel Haverich, Axel Muller, Paolo MacchiariniAbstract:Objective: A technique of hyperthermic isolated lung perfusion (ILP) chemotherapy was developed. Methods: Since April 1999, four patients with unilateral (n ¼ 2) or bilateral (n ¼ 2) sarcoma metastasis confined to a lobe (n ¼ 2) or entire lung (n ¼ 2) entered into a pilot study of hyperthermic (418C) ILP with high doses of cisplatin (70 mg/m 2 ). Eligibility included drug resistant metastasis and at least four previous surgical metastasectomies. The ILP of the lung segments was carried out following metastectomy, for 20–40 min at a rate of 0.3–0.5 l/min, a mean perfusion pressure lower than the own mean pulmonary artery pressure, and an Inflow Temperature of 418C or higher. Before and following ILP, the isolated lung segments were flushed with normothermic saline (1 l). Flow was continuously maintained by a centrifugal pump. Results: All patients successfully completed 31.7 ^ 9 min perfusion time at 41.4 ^ 0.38C, and this time-point corresponded to the maximal platinum lung-uptake (93.8 ng/mg tissue). The total vascular isolation was confirmed by continuously low systemic cisplatin plasma levels. There was no systemic drug-related toxicity but all patients experienced transient pulmonary toxicity as noncardiogenic edema of the treated lung segments. With a median follow-up of 12 months, three patients are alive and disease-free and one died from cerebral metastasis without autopsy evidence of local recurrence 13 months following ILP. Conclusion: Hyperthermic perfusion chemotherapy can be done safely and effectively. It represents a new treatment modality and deserves further investigations for patients with advanced, drug resistant or surgically refractory, lung sarcoma metastasis. However, further studies are needed to limit the ILP-induced pulmonary toxicity. q 2002 Elsevier Science B.V. All rights reserved.
-
Technique and results of hyperthermic (41°C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis
European Journal of Cardio-Thoracic Surgery, 2002Co-Authors: C Schröder, Stefan Fisher, Anne Christin Pieck, Hartmut Kirchner, Ulrich Jaehde, Axel Haverich, Axel Muller, Paolo MacchiariniAbstract:Objective: A technique of hyperthermic isolated lung perfusion (ILP) chemotherapy was developed. Methods: Since April 1999, four patients with unilateral (n ¼ 2) or bilateral (n ¼ 2) sarcoma metastasis confined to a lobe (n ¼ 2) or entire lung (n ¼ 2) entered into a pilot study of hyperthermic (418C) ILP with high doses of cisplatin (70 mg/m 2 ). Eligibility included drug resistant metastasis and at least four previous surgical metastasectomies. The ILP of the lung segments was carried out following metastectomy, for 20–40 min at a rate of 0.3–0.5 l/min, a mean perfusion pressure lower than the own mean pulmonary artery pressure, and an Inflow Temperature of 418C or higher. Before and following ILP, the isolated lung segments were flushed with normothermic saline (1 l). Flow was continuously maintained by a centrifugal pump. Results: All patients successfully completed 31.7 ^ 9 min perfusion time at 41.4 ^ 0.38C, and this time-point corresponded to the maximal platinum lung-uptake (93.8 ng/mg tissue). The total vascular isolation was confirmed by continuously low systemic cisplatin plasma levels. There was no systemic drug-related toxicity but all patients experienced transient pulmonary toxicity as noncardiogenic edema of the treated lung segments. With a median follow-up of 12 months, three patients are alive and disease-free and one died from cerebral metastasis without autopsy evidence of local recurrence 13 months following ILP. Conclusion: Hyperthermic perfusion chemotherapy can be done safely and effectively. It represents a new treatment modality and deserves further investigations for patients with advanced, drug resistant or surgically refractory, lung sarcoma metastasis. However, further studies are needed to limit the ILP-induced pulmonary toxicity. q 2002 Elsevier Science B.V. All rights reserved.
Yoshihiro Okuno - One of the best experts on this subject based on the ideXlab platform.
-
High-Temperature inert gas plasma magnetohydrodynamic energy conversion by using linear-shaped Faraday-type channel
Journal of Applied Physics, 2013Co-Authors: Tomoyuki Murakami, Yunqin Zhuang, Yoshihiro OkunoAbstract:We describe high-density magnetohydrodynamic (MHD) energy conversion in a high-Temperature seed-free argon plasma, for which a compact linear-shaped Faraday-type MHD electrical power generator is used. Short-time-duration single-pulse shock-tunnel-based experiments demonstrate the MHD energy conversion with varying total Inflow Temperature up to 9000 K and applied magnetic-flux density up to 4.0 T. The high-Temperature plasma is transformed from the thermal-equilibrium state at the entrance to the weak-nonequilibrium state in the supersonic MHD channel. The discharge structure is reasonably homogeneous without suffering from serious streamer development. The power generation performance is monotonically improved by increasing total Inflow Temperature and strength of magnetic field. The enthalpy extraction efficiency of 13.1% and overall power density of 0.16 GW/m3 are attained. The local power density at the middle of the channel reaches 0.24 GW/m3.
-
Simulation and demonstration of magnetohydrodynamic energy conversion in a high-Temperature inert gas
Physics of Plasmas, 2009Co-Authors: Tomoyuki Murakami, Yoshihiro OkunoAbstract:The present paper describes high-density magnetohydrodynamic(MHD) energy conversion in a high-Temperature seed-free argon plasma, for which a quasi-three-dimensional numerical simulation and a single-pulse shock-tunnel-based demonstration are conducted. The numerical model simulates the two-dimensional profiles of both the electron and the heavy-particle system of the supersonic argon plasma flow, of which the total Inflow Temperature is 8000 K. The MHD power-generating experiment clarifies the relationship between the plasma quality and the energy conversion efficiency as functions of the total Inflow Temperature (7600–9600 K) and the applied magnetic flux density (up to 4.0 T). The increase in the total Inflow Temperature from 7600 to 9400 K and the application of magnetic flux with density of 0.5–1.2 T change the plasma state; unstable behavior accompanied by an inhomogeneous structure is transformed to a homogeneous and stable state, which results in the significant improvement of the power generation performance. Even in low-density magnetic flux, the attained generator performance is comparable or superior to previous results obtained using a conventional low-Temperature seeded gas.
-
High-density magnetohydrodynamic energy conversion in a high-Temperature inert gas
Applied Physics Letters, 2008Co-Authors: Tomoyuki Murakami, Yoshihiro OkunoAbstract:We describe high-density magnetohydrodynamic (MHD) energy conversion in a high-Temperature seed-free argon plasma, for which a compact disk-shaped Hall-type radial-flow MHD electrical power generator is used. The state of the MHD power-generating plasma changes with increasing total Inflow Temperature from 8200to9400K; unstable behavior accompanied by the appearance of fine structures is transformed to a homogeneous and stable state. The attained enthalpy extraction efficiency is comparable to previous results using a conventional seeded gas. Furthermore, a high power output density is achieved even in relatively low-density magnetic flux.
-
High-density magnetohydrodynamic energy conversion
2008 IEEE 35th International Conference on Plasma Science, 2008Co-Authors: Tomoyuki Murakami, Yoshihiro OkunoAbstract:High-density energy conversion using a compact closed-cycle magnetohydrodynamics electrical power generator was described in this paper. Cesium-seeded argon gas was first used to demonstrate the conversion process. High power density (0.76 GW/m3 ) for outstanding efficient energy conversion was successful through the application of high- and uniform-density 4 T magnetic flux which enables high-Hall parameter operation, high electrical conductivity, due to a high seeding rate, symmetric and stable plasma creation, and a sufficient pressure gradient to drive a fluid. The feasibility of high-density MHD energy conversion in the high-Temperature seed-free argon plasma was also described. The state of the MHD power-generating plasma change with increasing total Inflow Temperature from 8200 K to 9400 K; the unstable behavior accompanied by fine structures is transformed to the homogeneous and stable state. The enthalpy extraction efficiency obtained under the high-Temperature condition is comparable with previous experiments using conventional seeded gases. Furthermore, the considerably high power output density of 0.3 GW/m3 is achieved even under the relatively low-density magnetic flux of 0.5 T
-
High-density MHD energy conversion in a seed-free argon plasma
39th Plasmadynamics and Lasers Conference, 2008Co-Authors: Tomoyuki Murakami, Yoshihiro OkunoAbstract:We describe high-density magnetohydrodynamic (MHD) energy conversion in a highTemperature seed-free argon plasma, where a compact disk-shaped Hall-type radial-flow MHD electrical power generator is used. The state of the MHD power-generating plasma changes with variations of total Inflow Temperature from 8200 K to 9400 K; the unstable behavior accompanied by fine structures is transformed to the homogeneous and stable state. The markedly high power output density is achieved even under the relatively lowdensity magnetic flux of 0.5 T. The attained enthalpy extraction efficiency is comparable to previous results using a conventional seeded gas.
Florian Kretschmer - One of the best experts on this subject based on the ideXlab platform.
-
Suitability Pre-Assessment of in-Sewer Heat Recovery Sites Combining Energy and Wastewater Perspectives
Energies, 2020Co-Authors: Franz J. T. Huber, Georg Neugebauer, Thomas Ertl, Florian KretschmerAbstract:In many countries around the world heating (and cooling) has been and will remain the biggest energy sector, but it is still widely dominated by fossil energy sources today. Wastewater as a source of renewable energy contains large amounts of heat and due to its place-bound localization in urban sewer systems it is usually also situated in very close distance to potential heat consumers. However, one has to keep in mind that heat extraction from wastewater might have undesired impacts on Temperature-sensitive treatment processes in the related wastewater treatment plant (WWTP). To assess the potential impact of in-sewer heat recovery on Inflow Temperature, two different approaches are available today: a simple (but less significant) alligation alternate, or very accurate (but less practical) mathematical models. To close the gap between practicability and significance this article introduces a novel approach to pre-assess the suitability of in-sewer heat recovery sites based on little and easily available data considering energy- and wastewater-related perspectives. A case study application demonstrates the informative value and general usability of the approach. Consequently, the proposed procedure can provide guidance and a template for related investigations at any place in a conventional (combined or separated) sewer system.
Anne Christin Pieck - One of the best experts on this subject based on the ideXlab platform.
-
technique and results of hyperthermic 41 c isolated lung perfusion with high doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis
European Journal of Cardio-Thoracic Surgery, 2002Co-Authors: C Schröder, Stefan Fisher, Anne Christin Pieck, Hartmut Kirchner, Ulrich Jaehde, Axel Haverich, Axel Muller, Paolo MacchiariniAbstract:Objective: A technique of hyperthermic isolated lung perfusion (ILP) chemotherapy was developed. Methods: Since April 1999, four patients with unilateral (n ¼ 2) or bilateral (n ¼ 2) sarcoma metastasis confined to a lobe (n ¼ 2) or entire lung (n ¼ 2) entered into a pilot study of hyperthermic (418C) ILP with high doses of cisplatin (70 mg/m 2 ). Eligibility included drug resistant metastasis and at least four previous surgical metastasectomies. The ILP of the lung segments was carried out following metastectomy, for 20–40 min at a rate of 0.3–0.5 l/min, a mean perfusion pressure lower than the own mean pulmonary artery pressure, and an Inflow Temperature of 418C or higher. Before and following ILP, the isolated lung segments were flushed with normothermic saline (1 l). Flow was continuously maintained by a centrifugal pump. Results: All patients successfully completed 31.7 ^ 9 min perfusion time at 41.4 ^ 0.38C, and this time-point corresponded to the maximal platinum lung-uptake (93.8 ng/mg tissue). The total vascular isolation was confirmed by continuously low systemic cisplatin plasma levels. There was no systemic drug-related toxicity but all patients experienced transient pulmonary toxicity as noncardiogenic edema of the treated lung segments. With a median follow-up of 12 months, three patients are alive and disease-free and one died from cerebral metastasis without autopsy evidence of local recurrence 13 months following ILP. Conclusion: Hyperthermic perfusion chemotherapy can be done safely and effectively. It represents a new treatment modality and deserves further investigations for patients with advanced, drug resistant or surgically refractory, lung sarcoma metastasis. However, further studies are needed to limit the ILP-induced pulmonary toxicity. q 2002 Elsevier Science B.V. All rights reserved.
-
Technique and results of hyperthermic (41°C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis
European Journal of Cardio-Thoracic Surgery, 2002Co-Authors: C Schröder, Stefan Fisher, Anne Christin Pieck, Hartmut Kirchner, Ulrich Jaehde, Axel Haverich, Axel Muller, Paolo MacchiariniAbstract:Objective: A technique of hyperthermic isolated lung perfusion (ILP) chemotherapy was developed. Methods: Since April 1999, four patients with unilateral (n ¼ 2) or bilateral (n ¼ 2) sarcoma metastasis confined to a lobe (n ¼ 2) or entire lung (n ¼ 2) entered into a pilot study of hyperthermic (418C) ILP with high doses of cisplatin (70 mg/m 2 ). Eligibility included drug resistant metastasis and at least four previous surgical metastasectomies. The ILP of the lung segments was carried out following metastectomy, for 20–40 min at a rate of 0.3–0.5 l/min, a mean perfusion pressure lower than the own mean pulmonary artery pressure, and an Inflow Temperature of 418C or higher. Before and following ILP, the isolated lung segments were flushed with normothermic saline (1 l). Flow was continuously maintained by a centrifugal pump. Results: All patients successfully completed 31.7 ^ 9 min perfusion time at 41.4 ^ 0.38C, and this time-point corresponded to the maximal platinum lung-uptake (93.8 ng/mg tissue). The total vascular isolation was confirmed by continuously low systemic cisplatin plasma levels. There was no systemic drug-related toxicity but all patients experienced transient pulmonary toxicity as noncardiogenic edema of the treated lung segments. With a median follow-up of 12 months, three patients are alive and disease-free and one died from cerebral metastasis without autopsy evidence of local recurrence 13 months following ILP. Conclusion: Hyperthermic perfusion chemotherapy can be done safely and effectively. It represents a new treatment modality and deserves further investigations for patients with advanced, drug resistant or surgically refractory, lung sarcoma metastasis. However, further studies are needed to limit the ILP-induced pulmonary toxicity. q 2002 Elsevier Science B.V. All rights reserved.